Skip to search formSkip to main content

Atu027

Known as: Anti-PKN3 siRNA Atu027 
A lipoplexed formulation consisting of short-interfering RNAs (siRNAs) directed against protein kinase N3 (PKN3) encapsulated in catiogenic and… Expand
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
2508 Background: Atu027 is a novel vascular stabilising, anti-metastatic, RNAi therapeutic, targeting systemic endothelial cell… Expand
Is this relevant?
2016
2016
385 Background: Atu027 is a liposomally formulated short interfering RNA with anti-metastatic activity, which silences expression… Expand
Is this relevant?
2016
2016
Agent Mechanism of action/target 196 [9] BBI-608 Cancer stemness inhibitor 341 [10] Demcizumab Humanized anti-DLL4 antibody 334… Expand
  • table 1
Is this relevant?
Highly Cited
2014
Highly Cited
2014
PURPOSE Atu027 is a novel liposomal RNA interference therapeutic that includes a short-interfering RNA (siRNA), which silences… Expand
Is this relevant?
2014
2014
siRNA clinical trials: state of the art With the emergence of siRNA-based nanomedicine as a powerful therapeutic strategy for… Expand
Is this relevant?
2012
2012
Chemically synthesized, small interfering RNAs (siRNA) are currently used as a new class of therapeutic molecules, allowing the… Expand
Is this relevant?
2012
2012
e13597 Background: Atu027 contains siRNA-lipoplexes, which elicits RNAi mediated suppression on PKN3 in vascular endothelial… Expand
Is this relevant?
2011
2011
3057 Background: Atu027 is a novel RNAi therapeutic based on cationic lipoplexes containing chemically stabilized siRNAs, which… Expand
Is this relevant?
2010
2010
PURPOSE Atu027, a novel RNA interference therapeutic, has been shown to inhibit lymph node metastasis in orthotopic prostate… Expand
Is this relevant?
Highly Cited
2008
Highly Cited
2008
We have previously described a small interfering RNA (siRNA) delivery system (AtuPLEX) for RNA interference (RNAi) in the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?